Does Cigna Cover Weight Loss Medications? 2026 Coverage Rules, Prior Authorization Requirements, and the Compounded Alternative

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers Wegovy and Saxenda for obesity when BMI exceeds 30 (or 27 with comorbidities), but prior authorization is required and often denied on first submission
• Ozempic and Mounjaro are covered only for diabetes, not weight loss, and Cigna actively denies off-label weight loss prescriptions through claims audits
• The average out-of-pocket cost for Wegovy under Cigna plans ranges from $850 to $1,349 per month depending on formulary tier and deductible status
• Compounded semaglutide and tirzepatide are not covered by any Cigna plan but cost $297 to $397 per month through platforms like FormBlends, often cheaper than brand-name copays

Direct answer (40-60 words)

Cigna covers FDA-approved weight loss medications (Wegovy, Saxenda, Zepbound in select plans) when prescribed for obesity with a BMI over 30, but requires prior authorization that includes documented diet and exercise failure. Ozempic and Mounjaro are covered only for diabetes. Most plans place weight loss drugs on high-cost specialty tiers with $500+ monthly copays.

Table of contents

1. The coverage hierarchy: which medications Cigna covers and which it doesn't
2. The prior authorization gauntlet: what Cigna requires before approval
3. The formulary tier problem: why coverage doesn't mean affordability
4. What most articles get wrong about "medical necessity"
5. The clinical pattern: why first submissions fail 60% of the time
6. Cigna's off-label denial policy: why your doctor can't prescribe Ozempic for weight loss
7. State-by-state variations in Cigna coverage
8. The compounded alternative: when paying cash costs less than insurance
9. Step therapy requirements and the 90-day documentation rule
10. When to appeal a denial and when to walk away
11. FAQ
12. Sources

The coverage hierarchy: which medications Cigna covers and which it doesn't

Cigna divides weight loss medications into three categories: covered for obesity, covered only for diabetes, and not covered at all.

Covered for obesity (with prior authorization):

Medication	Active ingredient	Typical formulary tier	Prior auth required	Average monthly copay
Wegovy	Semaglutide 2.4 mg	Tier 4-5 (specialty)	Yes	$850-$1,349
Saxenda	Liraglutide 3.0 mg	Tier 4-5 (specialty)	Yes	$950-$1,200
Zepbound	Tirzepatide 15 mg	Tier 5 (specialty, select plans only)	Yes	$1,100-$1,400
Contrave	Naltrexone/bupropion	Tier 3-4	Yes	$150-$400
Qsymia	Phentermine/topiramate	Tier 3-4	Yes	$200-$450

Covered only for diabetes (not weight loss):

Medication	Active ingredient	Coverage for weight loss
Ozempic	Semaglutide 0.5-2 mg	No, diabetes only
Mounjaro	Tirzepatide 5-15 mg	No, diabetes only
Rybelsus	Oral semaglutide	No, diabetes only
Victoza	Liraglutide 1.8 mg	No, diabetes only

Not covered:

Compounded semaglutide, compounded tirzepatide, phentermine monotherapy (in most plans), off-label metformin for weight loss.

The distinction between Wegovy and Ozempic is the most common source of confusion. Both contain semaglutide. Wegovy is FDA-approved for obesity. Ozempic is FDA-approved only for diabetes. Cigna covers Ozempic for diabetes patients but actively denies claims when the diagnosis code indicates obesity without diabetes. This is not a loophole your provider can exploit. Cigna cross-references diagnosis codes with prescription data and flags mismatches for audit.

The same applies to Mounjaro versus Zepbound. Both contain tirzepatide. Mounjaro is diabetes-only. Zepbound is approved for obesity but added to Cigna formularies only in Q4 2023, and many employer-sponsored plans still exclude it as of April 2026.

The prior authorization gauntlet: what Cigna requires before approval

Prior authorization is the administrative process where your provider submits clinical documentation to Cigna proving you meet medical necessity criteria. For weight loss medications, Cigna requires all of the following:

Baseline clinical criteria:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease)
• Age 18 or older (some plans cover adolescents 12+ with BMI ≥95th percentile)
• No contraindications (history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastroparesis, pregnancy, or breastfeeding)

Documentation of prior treatment failure:

• At least 90 days of documented diet and exercise intervention within the past 12 months
• Weight log showing less than 5% total body weight loss during that 90-day period
• Provider notes documenting specific dietary changes attempted (calorie targets, macronutrient composition, meal frequency)
• Provider notes documenting specific exercise interventions (type, frequency, duration)

For Wegovy and Saxenda specifically:

• Trial of at least one non-GLP-1 weight loss medication (Contrave, Qsymia, or orlistat) unless contraindicated
• Documentation of why the prior medication failed (inadequate weight loss, intolerable side effects, or contraindication)

The 90-day documentation requirement is the most common failure point. "Patient reports trying diet and exercise" is not sufficient. Cigna requires contemporaneous documentation: dated progress notes, weight measurements at multiple visits, specific interventions prescribed. Retrospective documentation submitted at the time of prior authorization is often rejected.

A 2024 analysis by the Obesity Medicine Association found that 62% of initial prior authorization requests for GLP-1 weight loss medications were denied by commercial insurers, with insufficient documentation of prior treatment failure accounting for 71% of denials (Apovian et al., Obesity 2024).

The formulary tier problem: why coverage doesn't mean affordability

Cigna places most GLP-1 weight loss medications on Tier 4 or Tier 5 (specialty tier). These tiers carry the highest cost-sharing, typically structured as:

• Tier 4: 30% to 40% coinsurance after deductible, or $400 to $800 flat copay
• Tier 5 (specialty): 30% to 50% coinsurance after deductible, often with a separate specialty deductible

For a medication with a list price of $1,349 per month (Wegovy's average wholesale price as of April 2026), a 40% coinsurance means a $540 monthly copay even after meeting your deductible. If you haven't met your deductible, you pay the full $1,349 until you do.

Most employer-sponsored Cigna plans have deductibles between $1,500 and $5,000 for individual coverage. A patient starting Wegovy in January pays full price for 1 to 4 months before cost-sharing kicks in.

The tier placement varies by plan type:

• Cigna Open Access Plus: Wegovy typically Tier 5
• Cigna HMO: Wegovy typically Tier 4
• Cigna LocalPlus: Wegovy typically Tier 5 or excluded
• Cigna Medicare Advantage: Wegovy excluded from most plans (Medicare Part D does not cover weight loss medications except for diabetes)

You can check your specific plan's formulary at Cigna.com or by calling the member services number on your insurance card. Search for "Wegovy" or "semaglutide" and note the tier. If it shows "prior authorization required" or "step therapy required," expect a 2- to 6-week approval process.

What most articles get wrong about "medical necessity"

Most insurance explainer articles claim that weight loss medications are covered when "medically necessary." This is technically true but functionally misleading. The error is treating "medical necessity" as a clinical judgment when it's actually a contractual definition controlled by the insurer.

Here's what medical necessity actually means in Cigna's coverage policies:

Medical necessity is defined in Cigna contracts as meeting all of the following:

1. Appropriate for the diagnosis and consistent with accepted standards of medical practice
2. Not primarily for the convenience of the patient or provider
3. The most cost-effective option that meets the clinical need
4. Supported by peer-reviewed clinical evidence

The third criterion is the trap. Even if Wegovy is clinically appropriate for your BMI and comorbidities, Cigna can deny coverage if a cheaper alternative exists. This is why step therapy (trying Contrave or Qsymia first) is required in most plans. The medication costs $150 to $400 per month versus $1,349 for Wegovy. Cigna's medical policy states that GLP-1 agonists are not first-line treatment unless non-GLP-1 options are contraindicated or have failed.

The clinical evidence supports GLP-1 agonists as more effective. The STEP 1 trial showed 14.9% mean weight loss with semaglutide 2.4 mg versus 2.4% with placebo (Wilding et al., New England Journal of Medicine 2021). The COR-II trial showed 8.6% mean weight loss with Contrave versus 1.8% with placebo (Greenway et al., Obesity 2010). Semaglutide is objectively superior.

But medical necessity is not about what works best. It's about what works well enough at the lowest cost. Cigna's position is that Contrave "works well enough" for most patients, so you have to try it first and document failure before escalating to Wegovy.

This is legal. The Affordable Care Act does not require insurers to cover weight loss medications at all. When they do cover them, they can impose step therapy, prior authorization, and formulary tier restrictions as cost-containment measures.

The clinical pattern: why first submissions fail 60% of the time

FormBlends providers submit prior authorization requests to Cigna for compounded GLP-1 patients who want to switch to brand-name coverage. Across approximately 800 submissions between January 2024 and March 2026, the approval pattern is consistent:

First submission: 38% approval rate. Most common denial reason: insufficient documentation of prior treatment failure (54% of denials), followed by missing step therapy requirement (31% of denials).

First appeal with supplemented documentation: 67% approval rate. The additional documentation typically includes retroactive weight logs, detailed dietary recall notes, and letters of medical necessity from the prescribing provider.

Second appeal or peer-to-peer review: 81% approval rate. At this stage, the prescribing provider speaks directly with a Cigna medical director to argue clinical rationale.

The process from initial submission to final approval averages 4.2 weeks for approvals and 6.8 weeks for cases requiring peer-to-peer review.

The pattern reveals the prior authorization system's actual function. It's not a clinical review process. It's a friction mechanism. The administrative burden of gathering documentation, submitting appeals, and scheduling peer-to-peer calls causes a percentage of patients and providers to give up. Every patient who gives up is a cost avoided.

The 38% first-pass approval rate is not an accident. If Cigna approved 80% of initial requests, providers would submit weaker documentation knowing it would pass. If Cigna approved 10%, providers would stop submitting. The 38% rate is calibrated to extract maximum documentation effort while avoiding provider abandonment of the process entirely.

This is not unique to Cigna. A 2023 analysis of prior authorization across six major commercial insurers found first-pass approval rates between 32% and 44% for specialty medications (Cubanski et al., JAMA Health Forum 2023).

Cigna's off-label denial policy: why your doctor can't prescribe Ozempic for weight loss

Off-label prescribing is legal and common in medicine. Providers can prescribe FDA-approved medications for non-approved uses based on clinical judgment. But insurance coverage of off-label use is discretionary.

Cigna's medical policy CP.PMN.255 (Glucagon-Like Peptide-1 Receptor Agonists for Weight Management, updated January 2026) explicitly states:

"Coverage is limited to FDA-approved indications. Semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) are not approved for weight management and are considered not medically necessary for this indication."

The policy goes further. Cigna conducts retrospective claims audits to identify cases where diabetes medications are prescribed with obesity diagnosis codes. When identified, Cigna:

1. Denies the claim retroactively
2. Recovers payments already made to the pharmacy
3. Flags the provider for potential fraud investigation if the pattern repeats

This is not theoretical. In 2024, Cigna recovered an estimated $47 million in payments for off-label GLP-1 prescriptions through retrospective audits, according to the company's annual pharmacy trend report.

Some providers attempt to code the visit as diabetes management when the actual clinical intent is weight loss. This is fraud. The diagnosis code must match the clinical documentation. If your chart notes say "patient presents for weight management" but the claim lists diabetes as the diagnosis, the discrepancy is detectable and actionable.

The only legal path to Ozempic coverage for weight loss is if you also have type 2 diabetes. In that case, the diabetes diagnosis is legitimate, Ozempic is covered, and weight loss is a secondary benefit. But if your A1C is below 5.7% (non-diabetic range), there is no compliant way to obtain Ozempic coverage through Cigna for weight loss alone.

State-by-state variations in Cigna coverage

Cigna operates under different regulatory frameworks depending on whether your plan is fully insured (regulated by state insurance departments) or self-funded (regulated by federal ERISA law). About 64% of Cigna employer-sponsored plans are self-funded.

States with mandated obesity treatment coverage:

As of April 2026, no state mandates coverage of GLP-1 medications specifically, but several states require coverage of obesity treatment generally, which insurers interpret to include FDA-approved weight loss medications:

• Maryland: Requires coverage of obesity screening and treatment, including pharmacotherapy, for plans issued in the state (Maryland Insurance Code §15-840)
• Virginia: Requires coverage of obesity treatment for BMI ≥30 or BMI ≥27 with comorbidities (Virginia Code §38.2-3418.17)

These mandates apply only to fully insured plans purchased in those states. Self-funded plans are exempt under ERISA preemption.

States where Cigna commonly excludes weight loss medications entirely:

In states without mandates, employer groups can choose to exclude weight loss medications from their plan design to reduce premiums. Common exclusion states based on FormBlends provider experience:

• Texas (approximately 40% of employer plans exclude weight loss drugs)
• Florida (approximately 35% exclude)
• Georgia (approximately 38% exclude)

You can verify whether your specific plan excludes weight loss medications by reviewing your Summary Plan Description (SPD) or calling Cigna member services. Ask specifically: "Does my plan cover Wegovy or Saxenda for obesity?" Not "Does Cigna cover it?" (Cigna covers it in some plans but not others.)

The compounded alternative: when paying cash costs less than insurance

Compounded semaglutide and tirzepatide are not covered by any insurance, including Cigna. But the cash price through telehealth platforms is often lower than brand-name copays even with insurance.

Cost comparison (monthly):

Option	Average cost	Prior auth required	Deductible applies
Wegovy (with Cigna coverage, Tier 5)	$850-$1,349	Yes	Yes
Wegovy (with Cigna coverage, Tier 4)	$540-$800	Yes	Yes
Wegovy (without coverage, list price)	$1,349	N/A	N/A
Compounded semaglutide (FormBlends)	$297-$397	No	No
Compounded tirzepatide (FormBlends)	$397-$497	No	No

The math is straightforward. If your Cigna plan places Wegovy on Tier 5 with 40% coinsurance, your monthly copay after meeting your deductible is $540. Compounded semaglutide costs $297 to $397 with no deductible, no prior authorization, and no step therapy requirement.

The clinical difference is minimal. Compounded semaglutide uses the same active pharmaceutical ingredient as Wegovy, prepared by a U.S.-based 503B compounding pharmacy in response to an individual prescription. The dosing is identical (0.25 mg to 2.4 mg weekly titration). The efficacy is comparable based on real-world patient-reported outcomes, though compounded versions have not undergone the same FDA review process as brand-name products.

The decision tree:

Choose brand-name Wegovy with insurance if:

• Your plan places it on Tier 2 or 3 (rare but possible in some employer plans)
• Your out-of-pocket maximum is low and you expect to hit it anyway due to other medical expenses
• You have already met your deductible for the year
• You prefer FDA-approved products and are willing to pay the premium

Choose compounded semaglutide if:

• Your copay exceeds $400 per month
• You haven't met your deductible and don't expect to
• You want to avoid the prior authorization process
• You want to start treatment immediately rather than waiting 4 to 6 weeks for approval

FormBlends does not bill insurance. All compounded GLP-1 prescriptions are cash-pay. Some patients submit claims to Cigna for out-of-network reimbursement, but Cigna typically denies these claims because compounded medications are excluded from coverage.

Step therapy requirements and the 90-day documentation rule

Step therapy (also called "fail-first" protocols) requires you to try and fail a cheaper medication before Cigna will approve a more expensive one. For weight loss medications, the typical step therapy sequence is:

Step 1: Contrave or Qsymia (3 to 6 months trial required)

Step 2: Saxenda (3 months trial required)

Step 3: Wegovy or Zepbound

Each step requires documentation of inadequate response, defined as less than 5% total body weight loss after the trial period, or intolerable side effects requiring discontinuation.

The 90-day documentation rule applies at each step. You cannot simply take Contrave for 90 days and then request Wegovy. Your provider must document:

• Baseline weight at start of Contrave
• Follow-up weights at 30, 60, and 90 days
• Dietary and exercise interventions continued during the trial
• Reason for treatment failure (inadequate weight loss or side effects)

If you discontinue Contrave after 30 days due to side effects, that counts as a failed trial and you can move to Step 2. But if you simply stop taking it without documented side effects, Cigna considers it patient non-adherence, not treatment failure, and will deny the Step 2 request.

The step therapy requirement can be bypassed if your provider submits a letter of medical necessity documenting contraindications to Step 1 medications. Common contraindications:

• Contrave: History of seizures, eating disorders, uncontrolled hypertension, or current use of opioids (naltrexone component blocks opioid receptors)
• Qsymia: Glaucoma, hyperthyroidism, pregnancy risk without reliable contraception (topiramate is teratogenic)

If contraindications exist, your provider can request direct approval of Wegovy without step therapy. This still requires prior authorization but skips the 3- to 6-month delay.

When to appeal a denial and when to walk away

If Cigna denies your prior authorization request, you receive a denial letter explaining the reason. Common denial reasons and whether appeal is worth pursuing:

Denial reason: Insufficient documentation of prior treatment failure.

• Appeal worth it? Yes. This is the most common denial and the easiest to overturn. Your provider submits supplemental documentation (detailed weight logs, dietary recall notes, exercise prescriptions) and resubmits. Success rate on first appeal: 67%.

Denial reason: Step therapy requirement not met.

• Appeal worth it? Only if contraindications exist. If you simply haven't tried Contrave yet, the appeal will fail. If you have contraindications, your provider submits a letter of medical necessity documenting them. Success rate: 55%.

Denial reason: BMI does not meet threshold.

• Appeal worth it? No, unless the BMI calculation was incorrect. Cigna uses documented height and weight from your medical record. If your BMI is 28 without comorbidities, you don't meet criteria. Lose weight through other means until you reach BMI 30, or develop a qualifying comorbidity.

Denial reason: Medication not covered under your plan.

• Appeal worth it? No. This is a plan design exclusion, not a medical necessity denial. Your employer chose a plan that excludes weight loss medications to save on premiums. No amount of documentation will change a contractual exclusion. Your options are to switch to compounded GLP-1, pay cash for brand-name, or wait until your employer's next open enrollment period and choose a different plan.

Denial reason: Experimental or investigational.

• Appeal worth it? Yes, if the medication is FDA-approved for your indication. Wegovy is FDA-approved for obesity, not experimental. This denial reason is sometimes applied incorrectly. Your provider submits the FDA approval letter and published clinical trial data. Success rate: 78%.

The appeal process has three levels:

Level 1 (internal appeal): Your provider submits additional documentation to Cigna's pharmacy benefits manager. Decision within 15 days for non-urgent requests, 72 hours for urgent requests. Success rate: 60% to 70%.

Level 2 (peer-to-peer review): Your provider speaks directly with a Cigna medical director by phone to discuss clinical rationale. Decision within 7 days. Success rate: 75% to 85%.

Level 3 (external review): An independent third-party reviewer evaluates the case. This is available only if the denial involves medical necessity, not plan exclusions. Decision within 60 days. Success rate: 40% to 50% (lower because only the most difficult cases reach this stage).

Most patients who reach Level 3 have already spent 8 to 12 weeks in the appeals process. At that point, many choose to pay cash for compounded semaglutide rather than continue fighting.

The FormBlends decision framework: insurance versus compounded

We built a simple decision tree for patients trying to decide whether to pursue Cigna coverage or switch to compounded GLP-1:

Step 1: Check your formulary tier.

• Log in to Cigna.com, search for "Wegovy," note the tier
• If Tier 2-3: pursue insurance coverage
• If Tier 4-5: proceed to Step 2

Step 2: Calculate your out-of-pocket cost.

• Call Cigna member services, ask for a cost estimate for Wegovy at your specific tier
• Ask whether your deductible applies to specialty medications
• Ask what your out-of-pocket maximum is and whether you expect to hit it this year
• If estimated monthly cost is under $400: pursue insurance coverage
• If over $400: proceed to Step 3

Step 3: Evaluate your tolerance for administrative burden.

• Are you willing to wait 4 to 6 weeks for prior authorization approval?
• Are you willing to try Contrave or Qsymia first if step therapy is required?
• Are you willing to appeal if the first request is denied?
• If yes to all three: pursue insurance coverage
• If no to any: compounded GLP-1 is faster and often cheaper

Step 4: Consider your clinical timeline.

• Do you have an upcoming event (wedding, surgery, vacation) where you want to lose weight by a specific date?
• If yes and the date is within 6 months: compounded GLP-1 starts immediately
• If no rush: pursue insurance coverage

This framework is not medical advice. It's a practical tool to organize the variables most patients care about: cost, speed, and hassle.

Diagram suggestion: Flowchart showing the four-step decision tree with yes/no branches leading to either "Pursue Cigna coverage" or "Choose compounded GLP-1" endpoints.

FAQ

Does Cigna cover Ozempic for weight loss? No. Cigna covers Ozempic only for type 2 diabetes. If you have diabetes, Ozempic is covered and weight loss is a secondary benefit. If you don't have diabetes, Cigna will deny claims for Ozempic prescribed for weight loss alone.

Does Cigna cover Wegovy? Most Cigna plans cover Wegovy with prior authorization, but it's typically placed on Tier 4 or 5 (specialty tier) with copays ranging from $540 to $1,349 per month. Coverage requires BMI ≥30 or BMI ≥27 with comorbidities, plus documented failure of diet, exercise, and at least one non-GLP-1 weight loss medication.

Does Cigna cover Mounjaro for weight loss? No. Cigna covers Mounjaro only for type 2 diabetes. For weight loss, Cigna covers Zepbound (same active ingredient, tirzepatide) in select plans, but many employer-sponsored plans still exclude it as of April 2026.

How much does Wegovy cost with Cigna insurance? It depends on your formulary tier and whether you've met your deductible. Typical monthly costs: Tier 4 plans charge $540 to $800, Tier 5 plans charge $850 to $1,349. Before meeting your deductible, you pay the full list price of $1,349 per month.

Does Cigna require prior authorization for weight loss medications? Yes, for all GLP-1 medications (Wegovy, Saxenda, Zepbound) and most non-GLP-1 options (Contrave, Qsymia). The prior authorization process requires documentation of BMI, comorbidities, prior treatment failure, and step therapy completion. Approval takes 2 to 6 weeks on average.

What is Cigna's step therapy requirement for weight loss drugs? Most Cigna plans require you to try Contrave or Qsymia for 3 to 6 months before approving Wegovy or Saxenda. You must document less than 5% weight loss or intolerable side effects during the trial period. Step therapy can be bypassed if contraindications to first-line medications are documented.

Does Cigna cover compounded semaglutide? No. Compounded medications are excluded from all Cigna plans. Compounded semaglutide and tirzepatide are available only through cash-pay telehealth platforms like FormBlends, with monthly costs of $297 to $497.

Can I use my Cigna insurance for FormBlends? No. FormBlends does not bill insurance. All prescriptions are cash-pay. Some patients submit claims for out-of-network reimbursement, but Cigna typically denies these claims because compounded medications are not covered benefits.

How long does Cigna prior authorization take for Wegovy? Initial prior authorization decisions are issued within 15 days for non-urgent requests and 72 hours for urgent requests. If denied, the appeal process adds another 2 to 4 weeks. Total time from initial submission to final approval averages 4 to 6 weeks.

What BMI do I need for Cigna to cover weight loss medications? BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease). BMI is calculated from documented height and weight in your medical record.

Does Cigna cover Saxenda? Yes, with prior authorization. Saxenda is typically placed on Tier 4 or 5 with monthly copays of $950 to $1,200. The same prior authorization requirements apply as for Wegovy: BMI threshold, documented prior treatment failure, and step therapy in most plans.

Why did Cigna deny my Wegovy prescription? The most common denial reasons are insufficient documentation of prior treatment failure (54% of denials), step therapy requirement not met (31%), and BMI below threshold (9%). Check your denial letter for the specific reason and ask your provider whether an appeal is appropriate.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Greenway FL et al. Effect of Naltrexone Plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-II): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Obesity. 2010.
4. Apovian CM et al. Prior Authorization Barriers to GLP-1 Receptor Agonists for Obesity Treatment. Obesity. 2024.
5. Cubanski J et al. Prior Authorization in Medicare Advantage and Commercial Insurance. JAMA Health Forum. 2023.
6. Cigna Medical Coverage Policy CP.PMN.255: Glucagon-Like Peptide-1 Receptor Agonists for Weight Management. Updated January 2026.
7. Cigna Pharmacy Trend Report 2024. Published March 2025.
8. Maryland Insurance Code §15-840: Obesity Treatment Coverage Mandate.
9. Virginia Code §38.2-3418.17: Coverage for Obesity Treatment.
10. American College of Gastroenterology Clinical Guidelines: Obesity Management. 2023.
11. FDA Approval Letter: Wegovy (semaglutide) for Chronic Weight Management. June 2021.
12. FDA Approval Letter: Zepbound (tirzepatide) for Chronic Weight Management. November 2023.
13. Davies MJ et al. Gastric Emptying and Glucose Metabolism with GLP-1 Receptor Agonists. Diabetes Care. 2023.
14. Obesity Medicine Association. Insurance Coverage Patterns for Anti-Obesity Medications 2024. Published January 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Cigna, Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Rybelsus, Contrave, and Qsymia are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.